Logo image of JUNS

JUPITER NEUROSCIENCES INC (JUNS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:JUNS - US48208B2034 - Common Stock

1.225 USD
+0.02 (+1.24%)
Last: 11/28/2025, 7:42:38 PM
1.21 USD
-0.02 (-1.22%)
After Hours: 11/28/2025, 7:42:38 PM
Fundamental Rating

1

Taking everything into account, JUNS scores 1 out of 10 in our fundamental rating. JUNS was compared to 192 industry peers in the Pharmaceuticals industry. JUNS may be in some trouble as it scores bad on both profitability and health. JUNS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year JUNS has reported negative net income.
In the past year JUNS has reported a negative cash flow from operations.
JUNS had negative earnings in each of the past 5 years.
In the past 5 years JUNS always reported negative operating cash flow.
JUNS Yearly Net Income VS EBIT VS OCF VS FCFJUNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

With a Return On Assets value of -148.65%, JUNS is not doing good in the industry: 85.94% of the companies in the same industry are doing better.
The Return On Equity of JUNS (-440.16%) is worse than 79.17% of its industry peers.
Industry RankSector Rank
ROA -148.65%
ROE -440.16%
ROIC N/A
ROA(3y)-1786.7%
ROA(5y)-1258.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JUNS Yearly ROA, ROE, ROICJUNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

1.3 Margins

JUNS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JUNS Yearly Profit, Operating, Gross MarginsJUNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, JUNS has more shares outstanding
JUNS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for JUNS has been reduced compared to a year ago.
JUNS Yearly Shares OutstandingJUNS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
JUNS Yearly Total Debt VS Total AssetsJUNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

JUNS has an Altman-Z score of -5.61. This is a bad value and indicates that JUNS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.61, JUNS is not doing good in the industry: 64.58% of the companies in the same industry are doing better.
JUNS has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
JUNS's Debt to Equity ratio of 0.11 is in line compared to the rest of the industry. JUNS outperforms 50.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -5.61
ROIC/WACCN/A
WACCN/A
JUNS Yearly LT Debt VS Equity VS FCFJUNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M -6M

2.3 Liquidity

A Current Ratio of 1.07 indicates that JUNS should not have too much problems paying its short term obligations.
JUNS has a worse Current ratio (1.07) than 80.73% of its industry peers.
A Quick Ratio of 1.07 indicates that JUNS should not have too much problems paying its short term obligations.
JUNS has a worse Quick ratio (1.07) than 75.52% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 1.07
JUNS Yearly Current Assets VS Current LiabilitesJUNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.67% over the past year.
EPS 1Y (TTM)46.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

JUNS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -89.45% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-420%
EPS Next 2Y78.89%
EPS Next 3Y-89.45%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JUNS Yearly Revenue VS EstimatesJUNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2025 2026 2027 2M 4M 6M 8M 10M
JUNS Yearly EPS VS EstimatesJUNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 -0.1 -0.2 -0.3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

JUNS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 20.02, which indicates a rather expensive current valuation of JUNS.
Based on the Price/Forward Earnings ratio, JUNS is valued a bit cheaper than 78.13% of the companies in the same industry.
JUNS is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.59, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 20.02
JUNS Price Earnings VS Forward Price EarningsJUNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JUNS Per share dataJUNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1 -0.15

4.3 Compensation for Growth

A cheap valuation may be justified as JUNS's earnings are expected to decrease with -89.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y78.89%
EPS Next 3Y-89.45%

More info and screens

0

5. Dividend

5.1 Amount

JUNS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JUPITER NEUROSCIENCES INC

NASDAQ:JUNS (11/28/2025, 7:42:38 PM)

After market: 1.21 -0.02 (-1.22%)

1.225

+0.02 (+1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)N/A N/A
Inst Owners0.23%
Inst Owner Change1602.22%
Ins Owners46.79%
Ins Owner Change0.09%
Market Cap42.18M
Revenue(TTM)N/A
Net Income(TTM)-5.90M
Analysts82.86
Price Target25.5 (1981.63%)
Short Float %0.15%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.72%
Min EPS beat(2)-63.4%
Max EPS beat(2)1.96%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.67%
PT rev (3m)-16.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-4%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 20.02
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 31.47
P/tB 31.47
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)0.06
Fwd EY5%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -148.65%
ROE -440.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1786.7%
ROA(5y)-1258.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.07
Quick Ratio 1.07
Altman-Z -5.61
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
EPS Next Y-420%
EPS Next 2Y78.89%
EPS Next 3Y-89.45%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-714.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-714.93%
OCF growth 3YN/A
OCF growth 5YN/A

JUPITER NEUROSCIENCES INC / JUNS FAQ

What is the ChartMill fundamental rating of JUPITER NEUROSCIENCES INC (JUNS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to JUNS.


What is the valuation status of JUPITER NEUROSCIENCES INC (JUNS) stock?

ChartMill assigns a valuation rating of 1 / 10 to JUPITER NEUROSCIENCES INC (JUNS). This can be considered as Overvalued.


How profitable is JUPITER NEUROSCIENCES INC (JUNS) stock?

JUPITER NEUROSCIENCES INC (JUNS) has a profitability rating of 0 / 10.


Can you provide the financial health for JUNS stock?

The financial health rating of JUPITER NEUROSCIENCES INC (JUNS) is 2 / 10.


What is the earnings growth outlook for JUPITER NEUROSCIENCES INC?

The Earnings per Share (EPS) of JUPITER NEUROSCIENCES INC (JUNS) is expected to decline by -420% in the next year.